SARS-CoV
4
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Vxco100
Research Leaders
5 sponsors active, led by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (4)
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Validation of a Rapid, Non-invasive Point-of-care IVD Test for Diagnosis of SARS-COV-2 (COVID-19) Infection
Nutritional Assessment of Hospitalized Patients With COVID-19
Research Network
Common Treatments
- Vxco1002
- Covid19 Mrna Vaccine1
- Easycov Poc1
- Nutritional Assessment1
Active Sponsors
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company2
- Firalis SA1
- Istanbul University1
- Medical Research Council, South Africa1
- Lille Catholic University1
Top Investigators
Istanbul University Istanbul Faculty of Medicine (ITF), Turkey
GHICL
Medical Research Council, South Africa
University of Maryland
Perinatal HIV Research Unit (PHRU)
Related Conditions
- Sarscov22
- Nutrition Disorders1